David Ho (L) and Yaoxing Huang (RenBio)
May 20, 2021 10:35 AM EDTUpdated May 21, 02:05 PM
Financing
Startups
Coronavirus

HIV re­searcher David Ho has a new line of at­tack on SARS-CoV-2, and his fledg­ling start­up is gun­ning for the clin­ic

Max Gelman

Senior Editor

The famed AIDS re­searcher David Ho start­ed off the Covid-19 pan­dem­ic work­ing to de­vel­op an an­ti­body against the SARS-CoV-2 virus, but now he’s be­hind a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times